JP6876301B2 - 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット - Google Patents
肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット Download PDFInfo
- Publication number
- JP6876301B2 JP6876301B2 JP2018018205A JP2018018205A JP6876301B2 JP 6876301 B2 JP6876301 B2 JP 6876301B2 JP 2018018205 A JP2018018205 A JP 2018018205A JP 2018018205 A JP2018018205 A JP 2018018205A JP 6876301 B2 JP6876301 B2 JP 6876301B2
- Authority
- JP
- Japan
- Prior art keywords
- gpc3
- recurrence
- hepatocellular carcinoma
- monoclonal antibody
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims description 103
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims description 103
- 238000000034 method Methods 0.000 title claims description 43
- 238000004590 computer program Methods 0.000 title claims description 19
- 102000010956 Glypican Human genes 0.000 claims description 187
- 108050001154 Glypican Proteins 0.000 claims description 187
- 108050007237 Glypican-3 Proteins 0.000 claims description 187
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 95
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 238000005259 measurement Methods 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 19
- 239000002683 reaction inhibitor Substances 0.000 claims description 13
- 239000007790 solid phase Substances 0.000 claims description 11
- 238000002372 labelling Methods 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 description 42
- 241000700721 Hepatitis B virus Species 0.000 description 39
- 238000001514 detection method Methods 0.000 description 36
- 239000000523 sample Substances 0.000 description 30
- 210000004899 c-terminal region Anatomy 0.000 description 23
- 239000000243 solution Substances 0.000 description 20
- 230000003287 optical effect Effects 0.000 description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 101800001415 Bri23 peptide Proteins 0.000 description 11
- 102400000107 C-terminal peptide Human genes 0.000 description 11
- 101800000655 C-terminal peptide Proteins 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000011257 definitive treatment Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 238000011088 calibration curve Methods 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000003656 tris buffered saline Substances 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000012752 Hepatectomy Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102400000874 N-terminal form Human genes 0.000 description 4
- 101800001340 N-terminal form Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- -1 for example Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000700739 Hepadnaviridae Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 102400000108 N-terminal peptide Human genes 0.000 description 2
- 101800000597 N-terminal peptide Proteins 0.000 description 2
- 241000700732 Orthohepadnavirus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JQXYBDVZAUEPDL-UHFFFAOYSA-N 2-methylidene-5-phenylpent-4-enoic acid Chemical compound OC(=O)C(=C)CC=CC1=CC=CC=C1 JQXYBDVZAUEPDL-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- WRVRNZNDLRUXSW-UHFFFAOYSA-N acetic acid;prop-2-enoic acid Chemical compound CC(O)=O.OC(=O)C=C WRVRNZNDLRUXSW-UHFFFAOYSA-N 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940064452 artec Drugs 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- SQNNHEYXAJPPKH-UHFFFAOYSA-N chloroethene;prop-2-enoic acid Chemical compound ClC=C.OC(=O)C=C SQNNHEYXAJPPKH-UHFFFAOYSA-N 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- YIXCPMSISWSKKS-FGCOXFRFSA-N ram-333 Chemical compound C1([C@]23CCN(C)[C@@H]([C@@]2(CCCC3)O)CC1=CC=C1OC)=C1OC1=CC=CC=C1 YIXCPMSISWSKKS-FGCOXFRFSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Data Mining & Analysis (AREA)
- Oncology (AREA)
- Primary Health Care (AREA)
- Genetics & Genomics (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
非特異反応抑制剤としては、測定で使用する抗体が目的抗原以外の物質に結合することを抑制するものであれば特に制限されない。具体的には、マウス血清、ヒツジ血清、ヤギ血清、マウス抗体及びヒツジ抗体、ヤギ抗体などが挙げられる。非特異反応抑制剤は市販されており、例えば、TRUBlock(Meridian Life Science社)、ASSAY DEVELOPMENT BLOCKING KIT(SCANTIBODIS LABORATOR社)、THBR2(株式会社特殊免疫研究所)等が知られている。
1)まず、無再発患者群から術前に得た血液試料と、再発患者群から術前に得た血液試料のそれぞれについて、GPC3濃度を測定する。
2)測定結果に基づいて、無再発の患者のGPC3濃度の値よりも高く、且つ、再発した患者のGPC3濃度の値よりも低い範囲から閾値を設定する。
好ましくは、無再発の患者とがんが再発した患者とを高精度に区別し得る値を、閾値として設定する。なお、後述の実施例では、GPC3濃度の閾値を15 pg/mLに設定している。本実施形態では、肝細胞がん患者の血液試料中のGPC3ペプチドの濃度を、上記のようにして予め設定された閾値と比較し、無再発患者群および再発患者群の何れに分類されるかが予測される。検査の結果として、たとえば、無再発患者群に分類される場合は再発リスクが低いという判定結果が出力され、再発患者群に分類される場合は再発リスクが高いという判定結果が出力される。
B型肝炎ウイルスの遺伝子型は特に限定されず、本願の出願日において既知のジェノタイプA〜J及びこれらのサブタイプ(例えばAa/1等)のいずれであってもよいし、将来発見され得る、本願の出願日において未知のジェノタイプであってもよい。
HCC患者血液サンプル39例は、患者からの同意を得て、国立がん研究センター東病院(千葉県柏市)にて肝切除治療前に採取し、遠心分離により血漿を取得した。このうち28例は肝切除治療後4年以内にHCCの再発が確認されており、11例は無再発であった。
健常人血漿サンプル50例はサンフコ社より購入した。いずれのサンプルも使用直前まで-80℃で凍結保存した。
さらに、実施例1で得られた測定結果で判定したGPC3陽性/陰性群について、再発リスク予測の有意差があるか検定した。再発の有無についてKaplan -Meier曲線を作成し、ログランク検定を行なったところ、図7に示す通りP値は0.0002となり、GPC3陽性群は有意に再発しやすい傾向が見られることが示された。なお、統計解析ソフトにはStatFlex ver.6(アーテック社)を用いた。
実施例1及び2で使用した抗体のエピトープを解析し、HCCの再発リスク判定精度が飛躍的に向上した理由が全長型GPC3を正しく捉えることであるかについて検証した。
検出用に用いたC末端認識型モノクローナル抗体のエピトープ解析は、図8のようなオーバーラッピングペプチド(表2)を用いた競合ELISAによって行なった。
捕捉用に用いたN末端認識型モノクローナル抗体のエピトープ解析は、図12のような部分リコンビナント蛋白質を用いたウェスタンブロット解析によって行なった。
GPC3の301番目から358番目のペプチドを認識する第一のN末端認識型モノクローナル抗体(ビオチン標識)と、GPC3の543番目から552番目のペプチドを認識する第二のC末端認識型モノクローナル抗体(アルカリフォスファターゼ標識)を用いて、自動免疫測定装置HISCL-800(シスメックス社)によって市販血漿10種(Proteogenex社)の測定を行った。なお、抗体のビオチン標識はBiotin Labeling Kit - SH(同仁化学研究所)を添付プロトコール通りに用いて行なった。
HCC患者血液サンプル39例のうち、4年以内に再発が見られた28例について、ウイルス感染の有無に基づく解析を実施した。再発群は年齢中央値68歳(63-72)であり、このうちHCV陽性は18例、HBV陽性は7例、ウイルス感染なしは3例であった。また、無再発期間は中央値10ヶ月(3-21)であった。
22 測定装置
33 判定装置
33a コンピュータ本体
33b 入力部
33c 表示部
301 受信部
302 記憶部
303 算出部
304 判定部
305 出力部
330 CPU
331 ROM
332 RAM
333 ハードディスク
334 入出力インターフェイス
335 読出装置
336 通信インターフェイス
337 画像出力インターフェイス
338 バス
340 記録媒体
500 箱
501 第1試薬容器
502 第2試薬容器
503 添付文書
Claims (8)
- グリピカン3(GPC3)の1〜358番目のアミノ酸配列を有するペプチドを認識する第1モノクローナル抗体と、アミノ酸配列TPKDNEISTFを認識する第2モノクローナル抗体と、血液試料とを混合する工程と、
前記第1モノクローナル抗体及び前記第2モノクローナル抗体の両方に認識されるGPC3ペプチドを測定する工程と
を含む、血液試料中のGPC3の測定値の取得方法。 - 前記血液試料が、肝細胞がん患者、肝細胞がんの発症が疑われる患者、又は肝細胞がんの再発が疑われる患者から採取した血液試料である請求項1に記載の方法。
- 前記測定値が、肝細胞がんの再発リスク診断を補助するための指標となる請求項1又は2に記載の方法
- 前記第1モノクローナル抗体又は前記第2モノクローナル抗体が、固相に固定化されている請求項1〜3のいずれか1項に記載の方法。
- 前記固相が、粒子である請求項4に記載の方法。
- 前記第1モノクローナル抗体又は前記第2モノクローナル抗体が、標識物質で標識されている請求項1〜5のいずれか1項に記載の方法。
- 測定工程が、非特異反応抑制剤の存在下で行われる、請求項1〜6のいずれか1項に記載の方法。
- プロセッサ及び前記プロセッサの制御下にあるメモリを含むコンピュータを備え、前記メモリには、血液試料中のグリピカン3(GPC3)ペプチドの測定値を取得するステップを前記コンピュータに実行させるためのコンピュータプログラムが記録されており、
前記GPC3ペプチドが、GPC3の1〜358番目のアミノ酸配列を有するペプチドを認識する第1モノクローナル抗体と、アミノ酸配列TPKDNEISTFを認識する第2モノクローナル抗体との両方に認識されるペプチドであり、
前記測定値が、肝細胞がんの再発リスク診断を補助するための指標となる、
血液試料中のGPC3の測定値を取得するための装置。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016047026 | 2016-03-10 | ||
JP2016047026 | 2016-03-10 | ||
JP2016185635 | 2016-09-23 | ||
JP2016185635 | 2016-09-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554923A Division JP6292564B2 (ja) | 2016-03-10 | 2017-03-06 | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018119966A JP2018119966A (ja) | 2018-08-02 |
JP6876301B2 true JP6876301B2 (ja) | 2021-05-26 |
Family
ID=59789314
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554923A Active JP6292564B2 (ja) | 2016-03-10 | 2017-03-06 | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット |
JP2018018205A Active JP6876301B2 (ja) | 2016-03-10 | 2018-02-05 | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554923A Active JP6292564B2 (ja) | 2016-03-10 | 2017-03-06 | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190066846A1 (ja) |
EP (1) | EP3428648B1 (ja) |
JP (2) | JP6292564B2 (ja) |
CN (1) | CN108738347B (ja) |
WO (1) | WO2017154839A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016164477A1 (en) * | 2015-04-06 | 2016-10-13 | Meso Scale Technologies, Llc. | High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus |
US10204791B1 (en) | 2017-09-22 | 2019-02-12 | Power Integrations, Inc. | Contact plug for high-voltage devices |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
ATE425461T1 (de) * | 2002-05-23 | 2009-03-15 | Sunnybrook & Womens College | Diagnose von hepatozellulärem karzinom |
AU2002330482A1 (en) * | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
US7691586B2 (en) * | 2004-04-28 | 2010-04-06 | Perseus Proteomics Inc. | Method for predicting and judging the recurrence of liver cancer after treating liver cancer |
MY145073A (en) * | 2004-07-09 | 2011-12-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
EP1813944A4 (en) * | 2004-10-05 | 2009-11-11 | Perseus Proteomics Inc | MEDICAMENT FOR CONTROLLING AGGRAVATION OF A HEPATITIS |
US8663929B2 (en) * | 2008-03-17 | 2014-03-04 | University Of Miyazaki | Method for detection of liver cancer cell using anti-glypican-3 antibody |
US9206257B2 (en) * | 2011-04-19 | 2015-12-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
CN104520331B (zh) * | 2012-06-01 | 2018-09-07 | 美国政府(由卫生和人类服务部的部长所代表) | 磷脂酰肌醇蛋白聚糖3的高亲和力单克隆抗体及其用途 |
WO2013191146A1 (ja) * | 2012-06-18 | 2013-12-27 | 独立行政法人国立がん研究センター | 悪性黒色腫(メラノーマ)の診断キット |
JP2014149172A (ja) * | 2013-01-31 | 2014-08-21 | Univ Of Tokushima | 新規なビーズアッセイシステム |
MX2016015162A (es) * | 2014-05-22 | 2017-03-03 | Genentech Inc | Anticuerpos anti - gpc3 e inmunoconjugados. |
JP2016095233A (ja) * | 2014-11-14 | 2016-05-26 | 国立研究開発法人国立がん研究センター | 早期肝細胞がん患者の再発リスクの予測を補助する方法、システム及びコンピュータプログラム製品 |
-
2017
- 2017-03-06 WO PCT/JP2017/008799 patent/WO2017154839A1/ja active Application Filing
- 2017-03-06 EP EP17763179.3A patent/EP3428648B1/en active Active
- 2017-03-06 JP JP2017554923A patent/JP6292564B2/ja active Active
- 2017-03-06 CN CN201780013771.6A patent/CN108738347B/zh active Active
-
2018
- 2018-02-05 JP JP2018018205A patent/JP6876301B2/ja active Active
- 2018-09-07 US US16/124,893 patent/US20190066846A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3428648B1 (en) | 2020-12-02 |
CN108738347B (zh) | 2022-01-14 |
CN108738347A (zh) | 2018-11-02 |
JP2018119966A (ja) | 2018-08-02 |
JPWO2017154839A1 (ja) | 2018-03-15 |
EP3428648A4 (en) | 2019-10-30 |
JP6292564B2 (ja) | 2018-03-14 |
US20190066846A1 (en) | 2019-02-28 |
WO2017154839A1 (ja) | 2017-09-14 |
EP3428648A1 (en) | 2019-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022083673A1 (zh) | 食管癌的生物标志物及其应用 | |
US10641780B2 (en) | Methods and compositions for treatment of autoimmune hepatitis | |
Qiao et al. | Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection | |
US20120295814A1 (en) | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer | |
JP2020016660A (ja) | クロモグラニンaを検出するための免疫アッセイ法および抗体 | |
JP6876301B2 (ja) | 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット | |
CN104812914B (zh) | 诊断受试者中的肝癌的方法及诊断肝癌的试剂盒 | |
JP5648905B2 (ja) | 肝臓がん発症の検出又はリスクの予測方法 | |
JP6893635B2 (ja) | 肝細胞がんの早期再発リスクの予測を補助する方法、装置及びコンピュータプログラム | |
JP2016095233A (ja) | 早期肝細胞がん患者の再発リスクの予測を補助する方法、システム及びコンピュータプログラム製品 | |
JP7315965B2 (ja) | ウィルス性肝癌の検出方法 | |
ES2939143T3 (es) | Biomarcadores para una politerapia que comprende lenvatinib y everolimus | |
CN113533739A (zh) | 辅助预测呼吸器感染症重症化及监测生物标志物测定值的方法、试剂盒、装置及计算机程序 | |
CN111108390A (zh) | 用于诊断胃癌的组合物和使用组合物进行诊断胃癌的方法 | |
US11231422B2 (en) | Methods and kits for predicting the risk of having or developping hepatocellular carcinoma in patients suffering from cirrhosis | |
JP7007665B2 (ja) | 生体の組織再生状態の判定方法 | |
WO2021024009A1 (en) | Methods and compositions for providing colon cancer assessment using protein biomarkers | |
EP4237855A1 (en) | Timp1 as a marker for cholangiocarcinoma | |
Rai et al. | Immunologic Approaches to Tumor Markers: Assays, Applications, and Discovery | |
US20160084851A1 (en) | Novel biomarkers | |
JP2016038214A (ja) | 卵巣癌の検出方法、卵巣癌と子宮内膜症との鑑別方法、並びに、キット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200207 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210324 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6876301 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE Ref document number: 6876301 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |